Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 22;15(13):3282.
doi: 10.3390/cancers15133282.

Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm

Violetta Rosiek  1 , Angelika Kogut  2 , Beata Kos-Kudła  1
Affiliations

Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm

Violetta Rosiek et al. Cancers (Basel). .

Abstract

There is a lack of effective biomarkers for diagnosing lung neuroendocrine neoplasms (LNENs). A known small cell lung cancer (SCLC) biomarker is a pro-gastrin-releasing peptide (ProGRP), but not for all LNENs, especially for bronchopulmonary carcinoids. This study aimed to evaluate the diagnostic value of ProGRP and chromogranin A (CgA) in diagnosing LNENs. The ProGRP and CgA levels in 290 cases of LNENs and 54 healthy controls (HCs) were measured. The median ProGRP concentration in the group of LNEN patients was 136.4 pg/mL, higher than that of HCs at 6.5 pg/mL. Most of the LNEN cohort was well-differentiated tumors (typical and atypical carcinoids, n = 262, 91.7% of all LNENs). The sensitivity, specificity, and area under the curve (AUC) of ProGRP when distinguishing LNENs vs. HCs were 94.8%, 100%, and 0.995. CgA (AUC = 0.375) could not determine LNENs vs. HCs. Therefore, based on these results, ProGRP may be considered as an effective marker for diagnosing LNENs.

Keywords: biomarker; chromogranin A (CgA); lung; neuroendocrine neoplasm (NEN); pro-gastrin-releasing peptide (ProGRP).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Performance of serum ProGRP and CgA for detecting lung neuroendocrine neoplasm (LNEN) patients. The receiver operating characteristic (ROC) curves and the area under the curves (AUC) for LNEN versus healthy controls are displayed. Individual ROC curves and AUC for serum ProGRP (AUC 0.995, 95% CI 0.990–1.000) and CgA (AUC 0.375, 95% CI 0.307–0.443).
See this image and copyright information in PMC

References

    1. Zhang Y.X., Yuan J., Gao Z.M., Zhang Z.G. LncRNA TUC338 promotes invasion of lung cancer by activating MAPK pathway. Eur. Rev. Med. Pharmacol. Sci. 2018;22:443–449. doi: 10.26355/eurrev_201801_14193. - DOI - PubMed
    1. Mao Y., Yang D., He J., Krasna M.J. Epidemiology of Lung Cancer. Surg. Oncol. Clin. N. Am. 2016;25:439–445. doi: 10.1016/j.soc.2016.02.001. - DOI - PubMed
    1. Bade B.C., Dela Cruz C.S. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin. Chest Med. 2020;41:1–24. doi: 10.1016/j.ccm.2019.10.001. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. WHO Classification of Tumours Editorial Board . In: WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Travis W.D., Brambilla E., Burke A.P., Marx A., Nicholson A.G., editors. World Health Organization; Lyon, France: 2015. - PubMed